Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,160 shares of the company’s stock after acquiring an additional 284 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IDEXX Laboratories were worth $4,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of IDXX. FDx Advisors Inc. purchased a new stake in IDEXX Laboratories during the 1st quarter worth about $210,000. Wells Fargo & Company MN lifted its holdings in IDEXX Laboratories by 15.1% during the 1st quarter. Wells Fargo & Company MN now owns 615,973 shares of the company’s stock worth $117,891,000 after buying an additional 80,947 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in IDEXX Laboratories by 13.3% during the 1st quarter. Daiwa Securities Group Inc. now owns 2,945 shares of the company’s stock worth $564,000 after buying an additional 346 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its holdings in IDEXX Laboratories by 200.4% during the 1st quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 12,556 shares of the company’s stock worth $2,360,000 after buying an additional 8,376 shares during the last quarter. Finally, Morse Asset Management Inc purchased a new stake in IDEXX Laboratories during the 1st quarter worth about $3,143,000. 86.85% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the company. Credit Suisse Group lifted their price target on IDEXX Laboratories from $255.00 to $259.00 and gave the stock an “outperform” rating in a report on Friday. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Piper Jaffray Companies boosted their target price on IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a report on Wednesday, August 1st. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Finally, Stifel Nicolaus boosted their target price on IDEXX Laboratories from $225.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, July 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $244.00.

In other news, VP Jacqueline Studer sold 8,598 shares of the business’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $242.37, for a total value of $2,083,897.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce L. Claflin purchased 415 shares of the company’s stock in a transaction that occurred on Friday, August 3rd. The stock was bought at an average price of $242.12 per share, for a total transaction of $100,479.80. Following the transaction, the director now directly owns 1,415 shares in the company, valued at $342,599.80. The disclosure for this purchase can be found here. Insiders sold a total of 10,699 shares of company stock valued at $2,515,943 over the last three months. Company insiders own 2.56% of the company’s stock.

IDEXX Laboratories stock opened at $243.50 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $146.09 and a fifty-two week high of $252.49. The company has a quick ratio of 0.73, a current ratio of 0.96 and a debt-to-equity ratio of -14.77. The stock has a market capitalization of $21.09 billion, a PE ratio of 74.24, a PEG ratio of 2.22 and a beta of 0.69.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.06. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The business had revenue of $580.75 million during the quarter, compared to the consensus estimate of $574.68 million. During the same period in the previous year, the business earned $0.87 EPS. The business’s quarterly revenue was up 14.1% on a year-over-year basis. equities research analysts expect that IDEXX Laboratories, Inc. will post 4.18 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: Understanding Relative Strength Index

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.